RT Journal Article
SR Electronic
T1 A Thermostable, Flexible RNA Vaccine Delivery Platform for Pandemic Response
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.02.01.429283
DO 10.1101/2021.02.01.429283
A1 Alana Gerhardt
A1 Emily Voigt
A1 Michelle Archer
A1 Sierra Reed
A1 Elise Larson
A1 Neal Van Hoeven
A1 Ryan Kramer
A1 Christopher Fox
A1 Corey Casper
YR 2021
UL http://biorxiv.org/content/early/2021/02/02/2021.02.01.429283.abstract
AB Current RNA vaccines against SARS-CoV-2 are limited by instability of both the RNA and the lipid nanoparticle delivery system, requiring storage at −20°C or −70°C and compromising universally accessible vaccine distribution. This study demonstrates the thermostability and adaptability of a nanostructured lipid carrier (NLC) RNA vaccine delivery system for use in pandemic preparedness and pandemic response. Liquid NLC is stable at refrigerated temperatures for ≥ 1 year, enabling stockpiling and rapid deployment by point-of-care mixing with any vaccine RNA. Alternatively, NLC complexed with RNA may be readily lyophilized and stored at room temperature for ≥ 8 months or refrigerated temperature for ≥ 21 months. This thermostable RNA vaccine platform could significantly improve distribution of current and future pandemic response vaccines, particularly in low-resource settings.One Sentence Summary An RNA vaccine delivery system stable at room temperature for 8+ months and refrigerated for 21+ months.Competing Interest StatementC.F. and N.V.H. are co-inventors on patent applications relating to PCT/US2018/37783, Nanostructured Lipid Carriers and stable emulsions and uses thereof. M.A., A.G., and R.K. are co-inventors on U.S. patent application nos. 63/075,032 and 63/107,383, Co-lyophilized RNA and Nanostructured Lipid Carrier. All other authors declare they have no competing interests.